-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Pancreatic cancer: difficult to treat and poor prognosis Metastatic pancreatic ductal adenocarcinoma (mPDAC) is a tumor with a very poor prognosis.
The disease is already at an advanced stage at the time of diagnosis, and there is currently a lack of effective treatment and control methods.
The patient's survival period is generally short
.
For these patients who have lost the opportunity for surgery, systemic palliative chemotherapy is a commonly used clinical measure to combat the rapid growth and metastasis of tumors
.
But the traditional method of chemotherapy obviously cannot meet the needs of pancreatic cancer treatment, because even with the most robust FOLFIRINOX regimen, the patient's median overall survival (OS) is only 11.
1 months
.
Immunotherapy for pancreatic cancer has not been successful.
In 2013, immunotherapy began to enter the field of oncology researchers
.
With the continuous increase of basic and clinical research evidence, immunotherapy for lung cancer and other tumors has been on the clinical track
.
However, the application of this therapy in pancreatic cancer has not been successful.
The reason is that pancreatic cancer is a "cold tumor", and current immunotherapy methods are difficult to activate the body's immune system of pancreatic cancer patients, so they cannot help patients overcome pancreatic cancer
.
So, is it really helpless for pancreatic ductal adenocarcinoma? Now, the turning point is coming.
What will a new type of oncolytic virus bring to the treatment of patients with advanced pancreatic cancer? Let's take a look at the cancer degree
.
Can the new oncolytic virus bring a turn for the immunotherapy of advanced pancreatic cancer? Oncolytic virus is a virus that specifically infects tumor cells.
While destroying tumor cells, it produces immunogenicity and effectively transforms "cold tumors" into "hot tumors".
At this time, the body's anti-tumor immune response can be activated
.
Thus, oncolytic immunotherapy was born
.
Parvovirus H1 (H-1PV) is a very potential oncolytic virus
.
Scientists have tried to explore the tumor suppressor effect of this virus in a preclinical model of PDAC
.
Currently in clinical trials, the ParvOryx02 study further explored the safety and preliminary efficacy of this therapy in clinical PDAC patients
.
ParvOryx02 is a single-arm, open-label, phase II clinical study to investigate the safety and efficacy of intravenous and intratumoral injection of H-1PV in patients with inoperable stage IV metastatic pancreatic ductal adenocarcinoma (at least one liver metastasis)
.
The 7 patients who met the criteria for entry and discharge were all those who failed the previous first-line systemic treatment and were able to receive second-line gemcitabine chemotherapy
.
The median progression-free survival and overall survival are considerable, and the lesions of some patients have significantly reduced the overall population.
The median progression-free survival (PFS) is more than 2 months (72 days), and the median overall survival (OS) is close to half a year (175) Days) (Picture 1)
.
For patients with metastatic pancreatic ductal adenocarcinoma receiving second-line treatment, the data is already very impressive
.
The tumors of 2 out of 7 patients shrank significantly, and the curative effect reached partial remission (PR)
.
Figure 1.
The overall survival (top) and progression-free survival (bottom) curves of patients.
H-1PV effectively activates tissue and blood immune-related markers.
Whether oncolytic immunity is successful or not depends fundamentally on whether the body's immune system is activated.
This can be determined by the detection of relevant immune markers in tissues and blood
.
After H-1PV infusion, the immune-related markers in the tissue changed (Figure 2)
.
Among the two patients with partial remission (Subject 4, 6), the concentration of IL-8, IL-9, IL-12, INF-α2, INF-γ increased significantly after H-1PV infusion, suggesting immune response and efficacy Relevance
.
Figure 2.
Changes of immune markers in tumor tissues over time There are also some miraculous changes in blood immune markers (Figure 3)
.
The neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), CD4+/CD8+ ratio and other markers related to immune activation have the same concentration changes in the two patients with partial remission.
(Figure 3A)
.
In addition, other immune-related markers, such as innate immunity-related HLA expression (Figure 3B), Treg cell-related expression markers (Figure 3C), etc.
, also showed consistent changes in the two patients with partial remission
.
These data indicate that H-1PV, a new type of oncolytic immunotherapy, has an immune-activating effect on some patients, and the formation of these immune microenvironments is conducive to fighting tumors
.
Figure 3.
The changes of relevant immune markers in blood over time are safe and feasible to treat.
No dose-limiting toxicity is observed.
Safety is the most important factor in early clinical research
.
No dose limiting toxicity (DLTs) was observed in the three dose groups
.
Most of the adverse events that occurred were controllable
.
This shows that H-1PV treatment is safe and feasible, and has the value of further exploring the efficacy and safety in a large sample
.
The new oncolytic immunity may help the treatment of advanced pancreatic cancer.
The early clinical research results show that H-1PV, as a new oncolytic immunotherapy, has shown a preliminary effect on metastatic pancreatic ductal adenocarcinoma
.
Its activating effect on tumor tissue and blood immunity suggests that oncolytic virus combined immunotherapy may be able to obtain better and longer-lasting efficacy data
.
Let us wait and see
.
For more anti-cancer information, welcome to download the Cancer Degree App! Reference: Jacek Hajda, et al.
Phase 2 trial of oncolytic H-1 parvovirus therapy shows safety and signs of immune system activation in patients with metastatic pancreatic ductal adenocarcinoma.
Clinical Cancer Research.
2021; DOI: 10.
1158/1078-0432.
CCR -21-1020.
Click below to learn more about clinical trial items Cancer Degree Jing/Color/Return/Gu 01020304 Swipe left and right to see more
The disease is already at an advanced stage at the time of diagnosis, and there is currently a lack of effective treatment and control methods.
The patient's survival period is generally short
.
For these patients who have lost the opportunity for surgery, systemic palliative chemotherapy is a commonly used clinical measure to combat the rapid growth and metastasis of tumors
.
But the traditional method of chemotherapy obviously cannot meet the needs of pancreatic cancer treatment, because even with the most robust FOLFIRINOX regimen, the patient's median overall survival (OS) is only 11.
1 months
.
Immunotherapy for pancreatic cancer has not been successful.
In 2013, immunotherapy began to enter the field of oncology researchers
.
With the continuous increase of basic and clinical research evidence, immunotherapy for lung cancer and other tumors has been on the clinical track
.
However, the application of this therapy in pancreatic cancer has not been successful.
The reason is that pancreatic cancer is a "cold tumor", and current immunotherapy methods are difficult to activate the body's immune system of pancreatic cancer patients, so they cannot help patients overcome pancreatic cancer
.
So, is it really helpless for pancreatic ductal adenocarcinoma? Now, the turning point is coming.
What will a new type of oncolytic virus bring to the treatment of patients with advanced pancreatic cancer? Let's take a look at the cancer degree
.
Can the new oncolytic virus bring a turn for the immunotherapy of advanced pancreatic cancer? Oncolytic virus is a virus that specifically infects tumor cells.
While destroying tumor cells, it produces immunogenicity and effectively transforms "cold tumors" into "hot tumors".
At this time, the body's anti-tumor immune response can be activated
.
Thus, oncolytic immunotherapy was born
.
Parvovirus H1 (H-1PV) is a very potential oncolytic virus
.
Scientists have tried to explore the tumor suppressor effect of this virus in a preclinical model of PDAC
.
Currently in clinical trials, the ParvOryx02 study further explored the safety and preliminary efficacy of this therapy in clinical PDAC patients
.
ParvOryx02 is a single-arm, open-label, phase II clinical study to investigate the safety and efficacy of intravenous and intratumoral injection of H-1PV in patients with inoperable stage IV metastatic pancreatic ductal adenocarcinoma (at least one liver metastasis)
.
The 7 patients who met the criteria for entry and discharge were all those who failed the previous first-line systemic treatment and were able to receive second-line gemcitabine chemotherapy
.
The median progression-free survival and overall survival are considerable, and the lesions of some patients have significantly reduced the overall population.
The median progression-free survival (PFS) is more than 2 months (72 days), and the median overall survival (OS) is close to half a year (175) Days) (Picture 1)
.
For patients with metastatic pancreatic ductal adenocarcinoma receiving second-line treatment, the data is already very impressive
.
The tumors of 2 out of 7 patients shrank significantly, and the curative effect reached partial remission (PR)
.
Figure 1.
The overall survival (top) and progression-free survival (bottom) curves of patients.
H-1PV effectively activates tissue and blood immune-related markers.
Whether oncolytic immunity is successful or not depends fundamentally on whether the body's immune system is activated.
This can be determined by the detection of relevant immune markers in tissues and blood
.
After H-1PV infusion, the immune-related markers in the tissue changed (Figure 2)
.
Among the two patients with partial remission (Subject 4, 6), the concentration of IL-8, IL-9, IL-12, INF-α2, INF-γ increased significantly after H-1PV infusion, suggesting immune response and efficacy Relevance
.
Figure 2.
Changes of immune markers in tumor tissues over time There are also some miraculous changes in blood immune markers (Figure 3)
.
The neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), CD4+/CD8+ ratio and other markers related to immune activation have the same concentration changes in the two patients with partial remission.
(Figure 3A)
.
In addition, other immune-related markers, such as innate immunity-related HLA expression (Figure 3B), Treg cell-related expression markers (Figure 3C), etc.
, also showed consistent changes in the two patients with partial remission
.
These data indicate that H-1PV, a new type of oncolytic immunotherapy, has an immune-activating effect on some patients, and the formation of these immune microenvironments is conducive to fighting tumors
.
Figure 3.
The changes of relevant immune markers in blood over time are safe and feasible to treat.
No dose-limiting toxicity is observed.
Safety is the most important factor in early clinical research
.
No dose limiting toxicity (DLTs) was observed in the three dose groups
.
Most of the adverse events that occurred were controllable
.
This shows that H-1PV treatment is safe and feasible, and has the value of further exploring the efficacy and safety in a large sample
.
The new oncolytic immunity may help the treatment of advanced pancreatic cancer.
The early clinical research results show that H-1PV, as a new oncolytic immunotherapy, has shown a preliminary effect on metastatic pancreatic ductal adenocarcinoma
.
Its activating effect on tumor tissue and blood immunity suggests that oncolytic virus combined immunotherapy may be able to obtain better and longer-lasting efficacy data
.
Let us wait and see
.
For more anti-cancer information, welcome to download the Cancer Degree App! Reference: Jacek Hajda, et al.
Phase 2 trial of oncolytic H-1 parvovirus therapy shows safety and signs of immune system activation in patients with metastatic pancreatic ductal adenocarcinoma.
Clinical Cancer Research.
2021; DOI: 10.
1158/1078-0432.
CCR -21-1020.
Click below to learn more about clinical trial items Cancer Degree Jing/Color/Return/Gu 01020304 Swipe left and right to see more
